ANDA 215219, held by Amneal. Clindamycin Phosphate.
As of Nov 15, 2026, ANDA 215219 (Clindamycin Phosphate), held by Amneal, was first approved by FDA on Nov 3, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 3, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin PhosphateEQ 1% BASE ยท gel;topical | Clindamycin Phosphate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
